A phase II trial of the rapamycin analog CCI-779 in previously treated mantle cell non-Hodgkin's lymphoma: Interim analysis of 18 patients.

被引：0
|
作者：
Witzig, TE
Geyer, SM
Salim, M
Inwards, DJ
Fonseca, R
Kauffnan, SH
Kurtin, P
Colgan, JP
Call, TG
Moore, D
White, WL
机构：
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] Allan Blair Canc Ctr, Regina, SK, Canada
[3] Canc Ctr Kansas, Wichita, KS USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2374
引用
收藏
页码：643A / 643A
页数：1
相关论文
共 50 条
  • [41] Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
    Robinson, K. Sue
    Williams, Michael E.
    van der Jagt, Richard H.
    Cohen, Philip
    Herst, Jordan A.
    Tulpule, Anil
    Schwartzberg, Lee S.
    Lemieux, Bernard
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) : 4473 - 4479
  • [42] A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b
    Oza, A. M.
    Elit, L.
    Provencher, D.
    Biagi, J. J.
    Panasci, L.
    Sederias, J.
    Dancey, J. E.
    Tsao, S.
    Eisenhauer, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] ACV and HGV infection in B-cell non-Hodgkin's lymphoma patients.
    Zignego, LA
    Ferri, C
    Giannini, C
    Monti, M
    Innocenti, F
    LaCivita, L
    Bellesi, G
    Gentilini, P
    HEPATOLOGY, 1996, 24 (04) : 1005 - 1005
  • [44] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    Atkins, MB
    Hidalgo, M
    Stadler, WM
    Logan, TF
    Dutcher, JP
    Hudes, GR
    Park, Y
    Lion, SH
    Marshall, B
    Boni, JP
    Dukart, G
    Sherman, ML
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 909 - 918
  • [45] A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma
    Torka, Pallawi
    Patel, Priyank
    Tan, Wei
    Wilding, Gregory
    Bhat, Seema A.
    Czuczman, Myron S.
    Lee, Kelvin P.
    Deeb, George
    Neppalli, Vishala
    Mavis, Cory
    Wallace, Paul
    Hernandez-Ilizaliturri, Francisco J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (01): : E51 - E60
  • [46] Temsirolimus Has Activity in Non-Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium
    Smith, Sonali M.
    van Besien, Koen
    Karrison, Theodore
    Dancey, Janet
    McLaughlin, Peter
    Younes, Anas
    Smith, Scott
    Stiff, Patrick
    Lester, Eric
    Modi, Sanjiv
    Doyle, L. Austin
    Vokes, Everett E.
    Pro, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) : 4740 - 4746
  • [47] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma
    Spina, Michele
    Simonelli, Cecilia
    Tirelli, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : E7 - E7
  • [48] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma
    Boue, Francois
    Gabarre, Jean
    Gisselbrecht, Christian
    Reynes, Jacques
    Cheret, Antoine
    Bonnet, Fabrice
    Billaud, Eric
    Raphael, Martine
    Lancar, Remi
    Costagliola, Dominique
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) : 4123 - 4128
  • [49] Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial
    Friedberg, Jonathan W.
    Vose, Julie M.
    Kelly, Jennifer L.
    Young, Faith
    Liesveld, Jane
    Armitage, James O.
    Proia, Nicole
    Cruttenden, Kim
    Leonard, John P.
    BLOOD, 2009, 114 (22) : 381 - 381
  • [50] Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial
    Park, H.
    Sanjeevaiah, A.
    Suresh, R.
    Mehta, R.
    Trikalinos, N.
    Bagegni, N.
    Aranha, O.
    Pedersen, K.
    Nixon, A.
    Jin, R.
    Mills, J.
    Fields, R.
    Amin, M.
    Lim, K.
    Tan, B.
    Grierson, P.
    Jiang, S.
    del Rosario, M.
    Wang-Gillam, A.
    Lockhart, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S132 - S132
12345